

<b>Patent No.</b>	<b>Reexam No.</b>	<b>Status</b>	<b>Claims Confirmed/Allowed by the Board</b>
5,436,960	90/006,533 90/006,675 90/007,731	Affirmed in part	4, 6, 11, 15, 17, 21, 23, 28, 32, 34, 38, 40, 45, 49, 51, 55, 57, 62, 67, 79
5,438,611	90/006,676	Affirmed	
5,479,472	90/006,677	Affirmed in part	10, 12, 14, 16, 18, 20, 29, 31, 33, 35, 37
5,625,670	90/006,491 90/006,678 90/007,723	Affirmed in part	567-570
5,631,946	90/006,492 90/006,679	Affirmed in part	289, 296-305, 307-309, 314- 329, 333
5,819,172	90/006,493 90/006,680 90/007,735	Affirmed	
6,067,451	90/006,494 90/006,681 90/007,726	Affirmed	
6,317,592	90/006,495 95/000,020	Affirmed	

36. After years of reexamination proceedings, the validity of claims 15, 32, and 34 of the '960 patent, which RIM was found to infringe at trial, have been upheld.

37. NTP has appealed the Board's decisions to the United States Court of Appeals for the Federal Circuit, as to those patent claims that the Board did not confirm. The appeal is pending.

#### **E. Defendant's Infringing Activities and Notice Thereof**

38. Defendants have been, currently are, and continue to directly and/or indirectly infringe one or more claims of the Campana Patents by making, using, selling, offering to sell and/or importing into the United States one or more products and/or services that infringe the Campana Patents or that are specially adapted for use in infringing products. Such activities include: (1) sales and distribution of infringing devices, software and services through retail